Name (Synonyms) | Correlation | |
---|---|---|
drug3446 | remdesivir Wiki | 0.58 |
drug2852 | Telemedicine follow-up visit Wiki | 0.58 |
drug1400 | In-person in clinic follow-up visit Wiki | 0.58 |
drug983 | Electronic Health Record Review Wiki | 0.58 |
drug880 | Diagnostic Laboratory Biomarker Analysis Wiki | 0.58 |
drug2312 | Questionnaire Administration Wiki | 0.44 |
drug837 | Data Collection Wiki | 0.41 |
drug1605 | Lopinavir/ritonavir Wiki | 0.18 |
drug1284 | Hydroxychloroquine Wiki | 0.06 |
There are 3 clinical trials
This study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help researchers determine how COVID-19 affects the outcomes of patients undergoing cancer treatment and how having cancer affects COVID-19.
Description: Distinguish the likelihood of severe COVID19 (for example, requiring hospitalization, requiring intensive care unit [ICU] treatment or requiring a ventilator) and death due to COVID-19 for patients with versus without the factor. Among subgroups of at least 50 patients, evaluate using chi-square tests as well as death and hospitalization rates.
Measure: Patient variables (factors) associated with severe acute respiratory syndrome (SARS) coronavirus 2 (COVID-19) severity Time: Up to 2 yearsDescription: Describe the degree to which COVID-19 interrupts, delays, or otherwise alters cancer treatment for subgroups of patients defined by cancer type and/or treatment modality. Describe the association between changes in cancer therapy and clinical outcomes. Evaluate association of COVID-19 with outcome by comparison to historical controls in subgroups of at least 50 patients using log rank tests to assess time to survival event.
Measure: Effects of COVID-19 on cancer therapy and association with clinical outcomes Time: Up to 2 yearsDescription: Analysis will include time to development of antibodies, prevalence of cytokine abnormalities, and genome-wide association study (GWAS) to define genetic polymorphisms associated with severe COVID-19 disease/mortality.
Measure: Collection of blood specimens for future biomarker studies Time: Up to 2 yearsThis study investigates convalescent plasma (CCP) collected from the blood of patients who have recovered from COVID-19 before use in treating patients with current COVID-19 infection. "Convalescent plasma" means that the plasma is coming from someone who has recovered from a COVID-19 infection. There may be antibodies present in CCP, that targets SARS-CoV-2, the virus responsible for COVID-19. The purpose of this study is to learn more about COVID-19 convalescent plasma and the effect it may have in treating COVID-19 infection.
Description: Will be assayed for severe acute respiratory syndrome (SARS‐CoV‐2) immunoassay, coronavirus (CoV) PepSeq assay, and SARS‐CoV‐2 lenti‐based neutralizing antibody titer.
Measure: Convalescent plasma (CCP) units infused in coronavirus disease-2019 (COVID-19) patients Time: Up to 12 months after enrollmentDescription: Will naturally be compared to reported data from the other studies. Analysis will focus on demonstrating that the antibody content of donor plasma increases the odds of surviving past day 28. Will also develop a nomogram for the probability of success (alive at day 28), accounting for patient, donor material and donor antibody characteristics measurable covariates.
Measure: All-cause mortality Time: At day 28 post-CCP infusionDescription: Will be examined to see how this relates to the duration of hospitalization.
Measure: Donor antibody levels Time: Up to 28 days post-CCP infusionDescription: Will be assessed on a 7-point ordinal scale, as recommended by the WHO patient outcome R&D Blueprint Group.
Measure: Incidence of adverse events Time: Up to 28 days post-CCP infusionDescription: Will be assessed on a 7-point ordinal scale. The scale is as follows: Death; Hospitalized, on invasive mechanical ventilation or ECMO; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, requiring low flow supplemental oxygen; Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than per protocol RDV administration); Not hospitalized
Measure: CCP recipient outcomes Time: Up to 28 days post-CCP infusionDescription: Patient can stay at the hospital for up to 28 days post-CCP infusion
Measure: Duration of hospitalization (days) Time: Up to 28 days post-CCP infusionDescription: Will be assessed on a 7-point ordinal scale.
Measure: Time to clinical improvement (days) Time: Up to 28 days post-CCP infusionThis study investigates a new diagnostic test in detecting SARS-CoV-2, the virus that causes the disease COVID-19. This may help to improve testing for COVID-19.
Description: Will use the standard-of-care (real time polymerase chain reaction [RT-PCR]) coronavirus disease 19 (COVID-19) test at the MD Anderson Molecular Diagnostic Lab result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the true result to estimate sensitivity with 95% confidence intervals. Estimates of sensitivity and specificity of the novel point-of-care diagnostic test will be provided separately for the provider-collected nasopharyngeal samples, the self-collected nasal swab, and the self-collected cheek swab.
Measure: Sensitivity of diagnostic test Time: Up to 1 yearDescription: Will use the standard-of-care (RT-PCR) COVID-19 test at the MD Anderson Molecular Diagnostic Lab result for SARS-CoV-2 as the true result to estimate specificity with 95% confidence intervals. Estimates of sensitivity and specificity of the novel point-of-care diagnostic test will be provided separately for the provider-collected nasopharyngeal samples, the self-collected nasal swab, and the self-collected cheek swab.
Measure: Specificity of diagnostic test Time: Up to 1 yearDescription: Will be estimated with 95% confidence intervals.
Measure: Concordance of the novel point-of-care diagnostic test Time: Up to 1 yearDescription: Will be estimated with 95% confidence intervals.
Measure: Positive predictive value (PPV) of the novel point-of-care diagnostic test Time: Up to 1 yearDescription: Will be estimated with 95% confidence intervals.
Measure: Negative predictive value (NPV) of the novel point-of-care diagnostic test Time: Up to 1 yearDescription: Will use descriptive statistics to summarize viral load metrics from the standard-of-care (RT-PCR) SARS-CoV-2 test and from each of the point-of-care tests.
Measure: Viral load metrics Time: Up to 1 monthDescription: Will use logistic regression methods to model progression to severe disease (defined as hospitalization) as a function of viral load, age, gender, smoking history, comorbidities, and symptoms for each of these tests.
Measure: Disease progression Time: Up to 1 month